Kaaks Rudolf, Berrino Franco, Key Timothy, Rinaldi Sabina, Dossus Laure, Biessy Carine, Secreto Giorgio, Amiano Pilar, Bingham Sheila, Boeing Heiner, Bueno de Mesquita H Bas, Chang-Claude Jenny, Clavel-Chapelon Françoise, Fournier Agnès, van Gils Carla H, Gonzalez Carlos A, Gurrea Aurelio Barricarte, Critselis Elena, Khaw Kay Tee, Krogh Vittorio, Lahmann Petra H, Nagel Gabriele, Olsen Anja, Onland-Moret N Charlotte, Overvad Kim, Palli Domenico, Panico Salvatore, Peeters Petra, Quirós J Ramón, Roddam Andrew, Thiebaut Anne, Tjønneland Anne, Chirlaque Ma Dolores, Trichopoulou Antonia, Trichopoulos Dimitrios, Tumino Rosario, Vineis Paolo, Norat Teresa, Ferrari Pietro, Slimani Nadia, Riboli Elio
Nutrition and Hormones Group, International Agency for Research on Cancer (IARC-WHO), Lyon, France.
J Natl Cancer Inst. 2005 May 18;97(10):755-65. doi: 10.1093/jnci/dji132.
Contrasting etiologic hypotheses about the role of endogenous sex steroids in breast cancer development among premenopausal women implicate ovarian androgen excess and progesterone deficiency, estrogen excess, estrogen and progesterone excess, and both an excess or lack of adrenal androgens (dehydroepiandrosterone [DHEA] or its sulfate [DHEAS]) as risk factors. We conducted a case-control study nested within the European Prospective Investigation into Cancer and Nutrition cohort to examine associations among premenopausal serum concentrations of sex steroids and subsequent breast cancer risk.
Levels of DHEAS, (Delta4-)androstenedione, testosterone, and sex hormone binding globulin (SHBG) were measured in single prediagnostic serum samples from 370 premenopausal women who subsequently developed breast cancer (case patients) and from 726 matched cancer-free control subjects. Levels of progesterone, estrone, and estradiol were also measured for the 285 case patients and 555 matched control subjects who had provided information about the day of menstrual cycle at blood donation. Conditional logistic regression models were used to estimate relative risks of breast cancer by quartiles of hormone concentrations. All statistical tests were two-sided.
Increased risks of breast cancer were associated with elevated serum concentrations of testosterone (odds ratio [OR] for highest versus lowest quartile = 1.73, 95% confidence interval [CI] = 1.16 to 2.57; P(trend) = .01), androstenedione (OR for highest versus lowest quartile = 1.56, 95% CI = 1.05 to 2.32; P(trend) = .01), and DHEAS (OR for highest versus lowest quartile = 1.48, 95% CI = 1.02 to 2.14; P(trend) = .10) but not SHBG. Elevated serum progesterone concentrations were associated with a statistically significant reduction in breast cancer risk (OR for highest versus lowest quartile = 0.61, 95% CI = 0.38 to 0.98; P(trend) = .06). The absolute risk of breast cancer for women younger than 40 followed up for 10 years was estimated at 2.6% for those in the highest quartile of serum testosterone versus 1.5% for those in the lowest quartile; for the highest and lowest quartiles of progesterone, these estimates were 1.7% and 2.6%, respectively. Breast cancer risk was not statistically significantly associated with serum levels of the other hormones.
Our results support the hypothesis that elevated blood concentrations of androgens are associated with an increased risk of breast cancer in premenopausal women.
关于内源性性激素在绝经前女性乳腺癌发生中的作用,不同的病因假说认为卵巢雄激素过多、孕酮缺乏、雌激素过多、雌激素和孕酮过多,以及肾上腺雄激素(脱氢表雄酮 [DHEA] 或其硫酸盐 [DHEAS])过多或缺乏均为风险因素。我们在欧洲癌症与营养前瞻性调查队列中开展了一项巢式病例对照研究,以检验绝经前血清性激素浓度与后续乳腺癌风险之间的关联。
在370例随后发生乳腺癌的绝经前女性(病例组)和726例匹配的无癌对照者的单次诊断前血清样本中,测量了DHEAS、(Δ4 -)雄烯二酮、睾酮和性激素结合球蛋白(SHBG)的水平。还对285例病例组患者和555例匹配的对照者测量了孕酮、雌酮和雌二醇的水平,这些对照者在献血时提供了月经周期日期信息。使用条件逻辑回归模型按激素浓度四分位数估计乳腺癌的相对风险。所有统计检验均为双侧检验。
乳腺癌风险增加与血清睾酮浓度升高(最高四分位数与最低四分位数的比值比 [OR] = 1.73,95%置信区间 [CI] = 1.16至2.57;P趋势 = 0.01)、雄烯二酮(最高四分位数与最低四分位数的OR = 1.56,95% CI = 1.05至2.32;P趋势 = 0.01)和DHEAS(最高四分位数与最低四分位数的OR = 1.48,95% CI = 1.02至2.14;P趋势 = 0.10)相关,但与SHBG无关。血清孕酮浓度升高与乳腺癌风险的统计学显著降低相关(最高四分位数与最低四分位数的OR = 0.61,95% CI = 0.38至0.98;P趋势 = 0.06)。对40岁以下女性随访10年,血清睾酮最高四分位数者乳腺癌的绝对风险估计为2.6%,而最低四分位数者为1.5%;孕酮最高和最低四分位数者,这些估计值分别为1.7%和2.6%。乳腺癌风险与其他激素的血清水平无统计学显著关联。
我们的结果支持以下假说,即绝经前女性血液中雄激素浓度升高与乳腺癌风险增加相关。